Starting December 2016 Lipigon joins the Astra Zeneca BioVentureHub located at AstraZeneca’s site in Mölndal, Sweden. The contract stretches over one year giving the Umeå University spin-off Company an office and full access to the whole facility, including infrastructure and capabilities.
The BioVentureHub is an initiative from AstraZeneca to support the Swedish life science ecosystem. It gives the participating companies the possibility to utilize AstraZeneca’s expertise and benefit from an innovative Environment.
– This is a great opportunity for Lipigon and we are pleased to join the BioVentureHub. Being part of the Hub will help us grow. We can utilize the expertise of AstraZeneca in all our projects and we will be part of an innovative environment where we also get closer to our existing collaboration partners – AstraZeneca and Antaros Medical. The flexible structure suits us perfectly. In the future, we can expand from having an office into having our own lab, says Stefan K Nilsson, CEO and co-founder at Lipigon.
The excitement is shared by AstraZeneca;
– I am particularly pleased to welcome Lipigon to the AstraZeneca BioVentureHub as it will enable us to work closely on our existing collaboration in the area of lipid disorders and stabilization of Lipoprotein Lipase (LPL), said Marcus Schindler, Vice President, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca.
– Lipigon are recognized for their expertise in the challenging area of LPL biology. Co-locating Lipigon’s team next to AstraZeneca’s drug discovery scientists will help accelerate our joint efforts to discover differentiated therapies while also strengthening the entire BioVentureHub ecosystem.
Lipigon and press contact
Lipigon is a spin out from Umeå University in Sweden. The company was founded by leading scientists in the field of cellular lipid transport. Lipigon is currently focusing on the discovery and development of novel treatments for dyslipidemia and metabolic diseases. At www.lipigon.se you can read all news, including this one at http://lipigon.se/article/lipigon-pharmaceuticals-joins-astrazenecas-bioventurhub.
For further information, please contact:Stefan K. Nilsson, CEO Lipigon Pharmaceuticals Phone: +46(0)705 78 17 68
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information please visit: www.astrazeneca.com
For more information please visit www.azbioventurehub.com